Background: Serotonin-noradrenaline reuptake inhibitors (SNRI) are widely used in medical practice. Their discontinuation has been associated with a wide range of symptoms. The aim of this paper is to identify the occurrence, frequency, and features of withdrawal symptoms after SNRI discontinuation. Methods: PRISMA guidelines were followed to conduct a systematic review. Electronic databases included PubMed, the Cochrane Library, Web of Science, and MEDLINE from the inception of each database to June 2017. Titles, abstracts, and topics were searched using a combination of the following terms: “duloxetine” OR “venlafaxine” OR “desvenlafaxine” OR “milnacipran” OR “levomilnacipran” OR “SNRI” OR “second generation antidepressant” OR “serotonin norepinephrine reuptake inhibitor” AND “discontinuation” OR “withdrawal” OR “rebound.” Only published trials in the English language were included. Results: Sixty-one reports met the criteria for inclusion. There were 22 double-blind randomized controlled trials, 6 studies where patients were treated in an open fashion and then randomized to a double-blind controlled phase, 8 open trials, 1 prospective naturalistic study, 1 retrospective study, and 23 case reports. Withdrawal symptoms occurred after discontinuation of any type of SNRI. The prevalence of withdrawal symptoms varied across reports and appeared to be higher with venlafaxine. Symptoms typically ensued within a few days from discontinuation and lasted a few weeks, also with gradual tapering. Late onset and/or a longer persistence of disturbances occurred as well. Conclusions: Clinicians need to add SNRI to the list of drugs potentially inducing withdrawal symptoms upon discontinuation, together with other types of psychotropic drugs. The results of this study challenge the use of SNRI as first-line treatment for mood and anxiety disorders.

Journal Section:
Editor's choice
Keywords:
Withdrawal symptoms, Serotonin-noradrenaline reuptake inhibitors, Adverse events, Discontinuation syndrome, Antidepressant drugs, Venlafaxine, Desvenlafaxine, Duloxetine, Milnacipran, Levomilnacipran
1.
Chouinard G, Chouinard VA: New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom 2015; 84: 63–71.
2.
Fava GA, Gatti A, Belaise C, Guidi J, Offidani E: Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom 2015; 84: 72–81.
3.
Wilson E, Lader M: A review of the man­agement of antidepressant discontinuation symptoms. Ther Adv Psychopharmacol 2015; 5: 357–368.
4.
Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL: Trends in prescription drug use among adults in the United States from 1999–2012. JAMA 2015; 314: 1818.
5.
Procyshyn RM, Bezchlibnyk-Butler KZ, Jeffries JJ: Clinical Handbook of Psychotropic drugs, ed 22. Boston, Hogrefe, 2017, pp 22–29.
6.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group: Methods of systematic reviews and meta-analysis: preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006–1012.
7.
Khan A, Musgnung J, Ramey T, Messig M, Buckley G, Ninan PT: Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg/d. J Clin Psychopharmacol 2014; 34: 365–368.
8.
Schagen van Leeuwen JH, Lange RR, Jonasson AF, Chen WJ, Viktrup L: Efficacy and safety of duloxetine in elderly women with stress urinary incontinence or stress-predominant mixed urinary incontinence. Maturitas 2008; 60: 138–147.
9.
Raskin J, Wiltse CG, Dinkel JJ, Walker DJ, Desaiah D, Katona C: Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. J Clin Psychopharmacol 2008; 28: 32–38.
10.
Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, Rickels K, Raskin J: Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 2008; 25: 182–189.
11.
Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF: Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry 1997; 154: 1760–1762.
12.
Liebowitz MR, Asnis G, Mangano R, Tzanis E: A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder. J Clin Psychiatry 2009; 70: 550–561.
13.
Saxe PA, Arnold LM, Palmer RH, Gendreau RM, Chen W: Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia. Curr Med Res Opin 2012; 28: 815–821.
14.
Sambunaris A, Bose A, Gommoll CP, Chen C, Greenberg WM, Sheehan DV: A phase III, double-Blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J Clin Psychopharmacol 2014; 34: 47–56.
15.
Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA: Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 2008 22; 24: 1877–1890.
16.
Boyer P, Montgomery S, Lepola U, Germain J-M, Brisard C, Ganguly R, Padmanabhan SK, Tourian KA: Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008; 23: 243–253.
17.
Raskin J, Pritchett YL, Wang F, D’Souza DN, Waninger AL, Iyengar S, Wernicke JF: A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005; 6: 346–356.
18.
Koponen H, Allgulander C, Erickson J, Dunayevich E, Pritchett Y, Detke MJ, Ball SG, Russell JM: Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry 2007; 9: 100–107.
19.
Allgulander C, Hackett D, Salinas E: Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001; 179: 15–22.
20.
Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB: Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44: 77–87.
21.
Tyrer P, Murphy S, Riley P: The Benzodiazepine Withdrawal Symptom Questionnaire. J Affect Disord 1990; 19: 53–61.
22.
Hartford J, Kornstein S, Liebowitz M, Pigott T, Russell J, Detke M, Walker D, Ball S, Dunayevich E, Dinkel J, Erickson J: Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 2007; 22: 167–174.
23.
Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D: Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicen ter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther 2009; 31: 1405–1423.
24.
Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA: Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002; 63: 225–231.
25.
Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Aström M, Brecher M: Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry 2009; 70: 526–539.
26.
Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M, Trivedi MH: A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl) 2015; 232: 2061–2070.
27.
Sechter D, Vandel P, Weiller E, Pezous N, Cabanac F, Tournoux A; study co-coordintors: A comparative study of milnacipran and paroxetine in outpatients with major depression. J Affect Disord 2004; 83: 233–236.
28.
Vandel P, Sechter D, Weiller E, Pezous N, Cabanac F, Tournoux A, Panconi E: Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine. Hum Psychopharmacol Clin Exp 2004; 19: 585–586.
29.
Montgomery SA, Huusom AKT, Bothmer J: A Randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004; 50: 57–64.
30.
Sir A, D’Souza RF, Uguz S, George T, Vahip S, Hopwood M, Martin AJ, Lam W, Burt T: Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry 2005; 66: 1312–1320.
31.
Wade A, Gembert K, Florea I: A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 2007; 23: 1605–1614.
32.
Chappell AS, Littlejohn G, Kajdasz DK, Scheinberg M, D’Souza DN, Moldofsky H: A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Clin J Pain 2009; 25: 365–375.
33.
Perahia DGS, Maina G, Thase ME, Spann ME, Wang F, Walker DJ, Detke MJ: Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70: 706–716.
34.
Rickels K, Montgomery SA, Tourian KA, Guelfi JD, Pitrosky B, Padmanabhan SK, Germain JM, Leurent C, Brisard C: Desvenlafaxine for the prevention of relapse in major depressive disorder. J Clin Psychopharmacol 2010; 30: 18–24.
35.
Rosenthal JZ, Boyer P, Vialet C, Hwang E, Tourian KA: Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder. J Clin Psychiatry 2013; 74: 158–166.
36.
Gallagher JC, Strzinek RA, Cheng RJ, Ausmanas MK, Astl D, Seljan P: The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause. J Womens Health 2012; 21: 188–198.
37.
Ninan PT, Musgnung J, Messig M, Buckley G, Guico-Pabia CJ, Ramey TS: Incidence and timing of taper/posttherapy-emergent adverse events following discontinuation of desvenlafaxine 50 mg/d in patients with major depressive disorder. Prim Care Companion CNS Disord 2015, 17.
38.
Dallal A, Chouinard G: Withdrawal and rebound symptoms associated with abrupt discontinuation of venlafaxine. J Clin Psychopharmacol 1998; 18: 343–344.
39.
Cohen LS, Soares CN, Lyster A, Cassano P, Brandes M, Leblanc GA: Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 2004; 24: 540–543.
40.
Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB: Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2003; 64: 1237–1244.
41.
Raskin J, Wang F, Pritchett YL, Goldstein DJ: Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med 2006; 7: 373–385.
42.
Perahia DGS, Quail D, Gandhi P, Walker DJ, Peveler RC: A randomized, controlled trial of duloxetine alone vs. duloxetine plus a telephone intervention in the treatment of depression. J Affect Disord 2008; 108: 33–41.
43.
Mago R, Forero G, Greenberg WM, Gommoll C, Chen C: Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study. Clin Drug Investig 2013; 33: 761–771.
44.
Tourian KA, Pitrosky B, Padmanabhan SK, Rosas GR: A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorder. Prim Care Companion CNS Disord 2011, 13.
45.
Ferguson JM, Tourian KA, Rosas GR: High-dose desvenlafaxine in outpatients with major depressive disorder. CNS Spectr 2012; 17: 121–130.
46.
Tint A, Haddad PM, Anderson IM: The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. J Psychopharmacol 2008; 22: 330–332.
47.
Baboolal NS: Venlafaxine withdrawal syndrome: report of seven cases in Trinidad. J Clin Psychopharmacol 2004; 24: 229–231.
48.
Haddad P, Devarajan S, Dursun S: Antidepressant discontinuation (withdrawal) symptoms presenting as “stroke.” J Psychopharmacol 2001; 15: 139–141.
49.
Benazzi F: Venlafaxine withdrawal symptoms. Can J Psychiatry 1996; 41: 487–487.
50.
Farah A, Lauer TE: Possible venlafaxine withdrawal syndrome. Am J Psychiatry 1996; 153: 576.
51.
Giakas WJ, Davis JM: Intractable withdrawal from venlafaxine treated with fluoxetine. Psychiatr Ann 1997; 27: 85–92.
52.
Jacobson N, Weiber R: Possible delayed venlafaxine withdrawal reaction: two case reports. Eur Psychiatry 1997; 12: 372–373.
53.
Boyd IW: Venlafaxine withdrawal reactions. Med J Aust 1998; 169: 91–92.
54.
Johnson H, Bouman WP, Lawton J: Withdrawal reaction associated with venlafaxine. BMJ 1998; 317: 787.
55.
Parker G, Blennerhassett J: Withdrawal reactions associated with venlafaxine. Aust NZ J Psychiatry 1998; 32: 291–294.
56.
Raby WN: Treatment of venlafaxine discontinuation symptoms with ondansetron. J Clin Psychiatry 1998; 59: 621–622.
57.
Luckhaus C, Jacob C: Venlafaxine withdrawal syndrome not prevented by maprotiline, but resolved by sertraline. Int J Neuropsychopharmacol 2001; 4: 43–44.
58.
Reeves RR, Mack JE, Beddingfield JJ: Shock-like sensations during venlafaxine withdrawal. Pharmacotherapy 2003; 23: 678–681.
59.
Hsiao MC, Liu CY: Withdrawal reactions associated with low-dose venlafaxine treatment in a patient with premenstrual dysphoric disorder. J Clin Psychiatry 2004; 65: 1147–1148.
60.
Khazaal Y: Mania after venlafaxine withdrawal in a patient with generalized anxiety disorder. Ann Pharmacother 2007; 41: 359–360.
61.
Stone TE, Swanson C, Feldman MD: Venlafaxine discontinuation syndrome and suicidal ideation. J Clin Psychopharmacol 2007; 27: 94–95.
62.
Hsiao MC, Liu CY: Successful duloxetine use to prevent venlafaxine withdrawal symptoms. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 576.
63.
Kotzalidis G, de Pisa E, Patrizi B, Savoja V, Ruberto G, Girardi P: Similar discontinuation symptoms for withdrawal from medium-dose paroxetine and venlafaxine after nine years in the same patient. J Psychopharmacol 2008; 22: 581–584.
64.
Clewes J: A Case Report of Onset of Tinnitus Following Discontinuation of Antidepressant and a Review of the Literature. Prim Care Companion CNS Disord 2012, p 14.
65.
Wang J, Greenberg H: Status cataplecticus precipitated by abrupt withdrawal of venlafaxine. J Clin Sleep Med 2013; 9: 715–716.
66.
Cutler N: Severe Venlafaxine Withdrawal Successfully Treated With a Short Course of Duloxetine. Prim Care Companion CNS Disord 2017, p 19.
67.
Qadir A, Haider N: Duloxetine withdrawal seizure. Psychiatry (Edgmont) 2006; 3: 10.
68.
Pitchot W, Ansseau M: Shock-like sensations associated with duloxetine discontinuation. Ann Clin Psychiatry 2008; 20: 175–175.
69.
Hou YC, Lai CH: Long-term duloxetine withdrawal syndrome and management in a depressed patient. J Neuropsychiatry Clin Neurosci 2014; 26:E04.
70.
Williams GW, Gandhi SJ, Altamirano A: An acute neurological syndrome with cerebrovascular and parkinsonian clinical features associated with perioperative SNRI withdrawal. J Neurosurg Anesthesiol 2013; 25: 353–354.
71.
Fava GA, Cosci F, Offidani E, Guidi J: Behavioral toxicity revisited: iatrogenic comorbidity in psychiatric evaluation and treatment. J Clin Psychopharmacol 2016; 36: 550–553.
72.
De las Cuevas C, de Leon J: Reviving research on medication attitudes for improving pharmacotherapy. Psychother Psychosom 2017; 86: 73–79.
73.
Fava GA, Guidi J, Rafanelli C, Rickels K: The clinical inadequacy of the placebo model and the development of an alternative conceptual framework. Psychother Psychosom 2017; 86: 332–340.
74.
Fava GA, Tomba E, Bech P: Clinical pharmacopsychology: conceptual foundations and emerging tasks. Psychother Psychosom 2017; 86: 134–140.
75.
Cosci F, Chouinard G, Chouinard V-A, Fava GA: The Diagnostic clinical Interview for Drug Withdrawal 1 (DID-W1): new symptoms of selective serotonin reuptake inhibitors (SSRI) or serotonin norepinephrine reuptake inhibitors (SNRI). Riv Psichiat 2018; 53: 95–99.
76.
Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA: The safety, tolerability and risks associated with the use of newer generation antidepressant drugs. Psychother Psychosom 2016; 85: 270–288.
77.
Fava GA: Can long-term treatment with antidepressant drugs worsen the course of depression? J Clin Psychiatry 2003; 64: 123–133.
78.
Fava GA: Rational use of antidepressant drugs. Psychother Psychosom 2014; 83: 197–204.
79.
Schueler YB, Koesters M, Wieseler B, Grouven U, Kromp M, Kerekes MF, Kreis J, Kaiser T, Becker T, Weinmann S: A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand 2011; 123: 247–265.
80.
Maund E, Tendal B, Hróbjartsson A, Jørgensen KJ, Lundh A, Schroll J, Gøtzsche PC: Benefits and harms in clinical trials of duloxetine for treatment of major depressive dis­order: comparison of clinical study reports, trial registries, and publications. BMJ 2014; 348:g3510.
81.
Chouinard G, Samaha AN, Chouinard VA, Peretti CS, Kanahara N, Takase M, Iyo M: Antipsychotic-induced dopamine supersensi­tivity psychosis: pharmacology, criteria, and therapy. Psychother Psychosom 2017; 86: 189–219.
82.
Spielmans GI: Duloxetine does not relieve painful physical symptoms in depression: a meta-analysis. Psychother Psychosom 2008; 77: 12–16.
© 2018 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.